Navigation Links
University of Minnesota Receives $40 Million for Type 1 Diabetes Research

MINNEAPOLIS and ST. PAUL, Minn., Dec. 11 /PRNewswire/ -- The University of Minnesota has received a $40 million pledge for diabetes research from the Richard M. Schulze Family Foundation. Goals for the funding, to be paid over five years, are to capitalize on the University's strength in diabetes research and to accelerate the timeline to translate it into a viable cure for people with type 1 diabetes.

The gift is the second largest in the history of the University and the second largest by an individual or family foundation to diabetes research in the United States. In recognition of the gift and the future of diabetes research, the University will rename its Diabetes Institute for Immunology and Transplantation (DIIT) the Schulze Diabetes Institute.

"We have the capacity to cure this devastating disease and help people enjoy a happy and productive life no longer constrained by diabetes and constant fears and worries," said Bernhard Hering, M.D., an internationally recognized diabetes researcher and co-director of the Schulze Diabetes Institute. "Curing type 1 diabetes is possible. We only need to declare it possible, engage the brightest minds, be contagiously committed and break all barriers. This gift, for which we are very grateful, is breaking big barriers by boosting resources, raising awareness and injecting a sense of urgency and responsibility."

Type 1 diabetes is a crippling and relentless disease. It occurs in children and young adults when the immune system mistakenly destroys all insulin-producing islet beta cells in the pancreas. To stay alive and to regulate their blood sugar, patients rely on multiple daily blood sugar measurements and insulin injections. Even with rigorous disease management, they are at risk of developing deadly complications.

"This transformative gift enables some of the world's best minds to aggressively pursue a cure for a disease impacting millions of people worldwide," said University president Robert Bruininks. "I want to personally thank the Schulze family for their leadership, passion and generosity. By focusing on such a widespread and devastating disease, they will not only transform lives, but the very nature of global health care."

Through pioneering work by researchers from the newly named Schulze Diabetes Institute, the Stem Cell Institute, the Center for Translational Medicine and other critical University resources, three promising conceptual cures have been identified: human islet transplantation, pig islet transplantation and stem cell-derived islet cells. The Schulze gift will focus on specific efforts to implement these cures.

"The scientists, especially Drs. Hering, Firpo and Blazar and their teams at the University have the passion, determination, experience and knowledge to find a cure for type 1 diabetes," said Richard M. Schulze. "We felt the time was right to choose a direction that would advance to a cure in the next five years. The University of Minnesota, its president and board are committed to collaborating internally and externally to make it the center of excellence it needs to be to accomplish this goal."

The collaborative effort to advance these cures will be led by Hering and Meri Firpo, Ph.D., of the Stem Cell Institute, with support from the Center for Translational Medicine, directed by Bruce Blazar, M.D. Resources throughout the University will be leveraged to achieve this ambitious goal. The pledge is based on achievement milestones that have been established for each year of funding.

Researchers have had success reversing diabetes with human islet cell transplants, but because of the severe shortage of donor organs, and the challenges of immunosuppression, few have benefited from this experimental treatment. University of Minnesota researchers have sought a cure for type 1 diabetes through developing both an abundant supply of islet cells and better and safer immunosuppressant techniques.

A team led by David Sutherland, M.D., Ph.D., co-director of the Schulze Diabetes Institute and founder of the former DIIT, was the first to perform a human islet transplant, in 1974. Since then, Hering, Sutherland and others have established the protocol standard for human islet transplantation. They are continually improving outcomes by refining the process to minimize the number of cells used and the need for immunosuppressive drugs. Nearly 90 percent of patients who have undergone the procedure are now insulin-independent.

The research team has also successfully reversed diabetes in animal models using pig islet cells and has established a relationship with Spring Point Project, a nonprofit organization that raises medical-grade pigs to supply islets for transplantation. The researchers are currently developing a cell therapy to offset immunosuppression issues related to transplant.

Firpo is investigating the reprogramming of adult skin cells into stem cells that can generate islet cells. She also uses stem cells to study the development of the cells and tissues involved with the diabetes, with the hope that better understanding may lead to discoveries that would enable islet cell regeneration or prevent the islet cells from being destroyed in the first place.

"This most generous gift positions us to collaborate on the unprecedented and real opportunities that exist today in stem cell, transplantation and immunology research. These synergies will help us find the best cure faster. Stem cells provide another source of islets for transplantation and offer us tremendous potential to conquer this complicated disease," said Firpo.

Internal and external advisory boards will provide insight, feedback and oversight throughout the process. Researchers will also be collaborating with partners from other academic institutions and industry partners.

Founded in 1939, the Minnesota Medical Foundation raises millions of dollars annually for health-related research, education and service at the University of Minnesota, with gifts supporting research, academic programs, faculty positions, scholarships, facilities and equipment purchases. Gifts directed to research fund studies related to children's health, public health, cancer, heart and lung disease, diabetes, infectious diseases and other critical illnesses. For more information about the foundation, please call 612-625-1440 or visit

The Richard M. Schulze Family Foundation, established in 2004, is committed to improving the lives of families and children in Minneapolis and St. Paul, Minnesota, and surrounding communities through programs that support medical research, social services and K-8 education.

Contact: Molly Portz, Academic Health Center, 612-625-2640

Sarah Youngerman, Minnesota Medical Foundation, 612-626-5378

SOURCE University of Minnesota
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
2. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
3. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
4. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
5. Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman
6. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
7. SpineSmith Partners Collaborates with University of Texas Biomedical Engineering Students to Develop Innovative Products
8. Nikon Instruments Provides Donation to Help Clemson University Start New Core Microscopy Facility
9. Medical Simulation Corporation Announces Partnership With University of South Florida
10. Winning University of Melbourne Ph.D. research boosts the search for sensitive sensors
11. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Post Your Comments:
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... behalf of the Toronto Stock Exchange, confirms that as ... no corporate developments that would cause the recent movements ... --> About Aeterna Zentaris Inc. ... --> Aeterna Zentaris is a specialty biopharmaceutical company ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) announced ... in the Piper Jaffray 27 th Annual Healthcare Conference in ... 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). --> ... Financial Officer, will participate in the Piper Jaffray 27 th ... NY on Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):